Polymerase News and Research

RSS

Is a ten day isolation period for COVID-19 patients long enough?

In a new study researchers at the Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, Brazil, reported that mild COVID-19 patients can still be infectious at day 10 from the illness onset, even in the absence of symptoms.

8 Feb 2021

Visualization of SARS-CoV-2 RNA by fluorescence in situ hybridization probes

A team of scientists from France has recently designed fluorescence in situ hybridization probes (CoronaFISH) to visualize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in infected cells. A detailed description of the probe design, validation, and application is currently available on the bioRxiv preprint server.

7 Feb 2021

Research shows intestinal parasite infestations reduce COVID-19 severity

Now, new research out of Mekelle, Ethiopia, examines the role of parasitic infestation on the prognosis of COVID-19. The research paper, which appears on the preprint server medRxiv, shows that intestinal parasitosis is protective against severe COVID-19.

4 Feb 2021

Chronic hypoxia upregulates RNA polymerase I, alters methylation on ribosomal RNAs

Hypoxia -- where a tissue is deprived of an adequate supply of oxygen -- is a feature inside solid cancer tumors that renders them highly invasive and resistant to treatment. Study of how cells adapt to this critical stressor, by altering their metabolism to survive in a low-oxygen environment, is important to better understand tumor growth and spread.

4 Feb 2021

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

The phase 3 human trial is the last stage of clinical evaluation, showing how effective and safe a drug or vaccine is. In this case, the Gam- Sputnik V showed a consistent strong protective effect across all participant age groups.

3 Feb 2021

Hematological findings in Amazonian patients with COVID-19

To discriminate between patients with severe and non-severe COVID-19 quickly, researchers from Peru looked for prognostic signatures in the blood samples of COVID-19 patients. Virgilio E. Failoc-Rojas et al. examined laboratory results and clinical prognosis of COVID-19 patients from a hospital in the Peruvian Amazon.

3 Feb 2021

Viral load the main driver of SARS-CoV-2 transmission

A study conducted by researchers in the UK and Spain suggests that viral load is the main determinant of transmission risk in cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

Rapid SARS-CoV-2 antigen test improved with silver amplification

A new preprint posted to the medRxiv server describes the use of silver amplification technology to develop a sensitive, rapid antigen test for COVID-19.

2 Feb 2021

ACE2 agonist C21 relieves respiratory difficulty in COVID-19

A new study describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting enzyme 2 (ACE2), the host cell receptor that facilitates viral entry.

2 Feb 2021

Albumin: The Natural Choice for Diagnostic Tests

The availability of established diagnostic kits has enabled researchers to plug-and-play in the design of COVID-19 diagnostics. Such technologies took decades to optimize, but they are now playing an important role in identifying and managing the spread of COVID-19. Recombumin® provides an enhanced solution as part of this toolbox for dealing with this disease

From Albumedix Ltd. 2 Feb 2021

Why SARS-CoV-2 B.1.1.7 is more virulent

A new preprint research paper by scientists from Sweden and India attempts to provide a preliminary answer to these questions using computational modeling. The research, which appears on the bioRxiv* server, predicts increased virulence with the new variant. If validated, this could help public health authorities prepare for new variants' possible impact as they emerge.

2 Feb 2021

New platform using green algae tests for SARS-CoV-2 virus

Researchers at the University of California, San Diego, have demonstrated the potential of using green algae to make recombinant viral proteins that could be used in large scale assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

1 Feb 2021

Ivermectin may not be the ‘silver bullet’ antiviral against COVID-19

A team of researchers based in Peru and the U.S. recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19.

1 Feb 2021

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Gene panel is effective at identifying problematic genes in common leukemia

A gene panel that looks for about 10 times the number of cancer-causing genes as panels currently used to diagnose and fine-tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia, investigators report.

1 Feb 2021

New COVID-19 test uses a smartphone microscope to quickly analyze saliva samples

Researchers at the University of Arizona are developing a COVID-19 testing method that uses a smartphone microscope to analyze saliva samples and deliver results in about 10 minutes.

29 Jan 2021

Viruses like SARS-CoV-2 may be more widespread than previously thought

Researchers in Cambodia, France, and the United States have conducted a study indicating that viruses related to SARS-CoV-2 – the agent that causes COVID-19 – are far more geographically widespread than previously thought.

28 Jan 2021

Innovative breakthrough promises to diagnose DNA rearrangement mutations

Doctors are increasingly using genetic signatures to diagnose diseases and determine the best course of care, but using DNA sequencing and other techniques to detect genomic rearrangements remains costly or limited in capabilities.

28 Jan 2021

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.

27 Jan 2021